EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults

Yanlu Huang, Lin Huang, Liang Cui, Fengfeng Pan, Fang Xie iD, Hongbo Guo, Qihao Guo, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia · 2026-10 · 22 (10)

DOI: 10.1002/alz.71922 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 20.10.2026. Verfasst von Yanlu Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, Shenzhen Qianhai Taikang Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: tau Proteins, Positron-Emission Tomography, Amyloid beta-Peptides, Cognition. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute on Aging (NIA), National Institutes of Health (NIH), National Science and Technology Major Project of China, STI2030-Major Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Plasma phosphorylated tau (p‐tau)217 is increasingly used to triage amyloid testing, but the biological and clinical meaning of discordant plasma p‐tau217 and amyloid positron emission tomography (PET) results in cognitively normal adults remains uncertain. METHODS We analyzed cognitively normal participants from the Chinese Preclinical Alzheimer's Disease Study (CPAS; n = 594) and the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 475). Amyloid PET positivity was defined as Centiloid ≥ 20. Cohort‐specific p‐tau217 positivity was defined using PET‐anchored cutoffs with ≥ 0.90 specificity, yielding four p‐tau/PET groups. Linear models assessed cross‐sectional biomarker and cognitive differences; mixed‐effects and Cox models assessed ADNI longitudinal Centiloid accumulation, cognitive trajectories, and clinical progression. RESULTS In cross‐sectional analyses, compared to p‐tau−/PET−, p‐tau+/PET− had higher glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels across cohorts; p‐tau−/PET+ showed a lower plasma amyloid beta 42/40 ratio in ADNI; and p‐tau+/PET+ showed the broadest multimodal abnormalities. In ADNI, both p‐tau+ groups had higher clinical progression risk and faster decline in selected cognitive domains; both PET+ groups showed faster Centiloid accumulation. Faster Centiloid accumulation in p‐tau+/PET− was observed only at lower specificity thresholds. DISCUSSION Discordant plasma p‐tau217 and amyloid PET results should be interpreted according to both the positivity pattern and the p‐tau217 cutoff applied. Distinguishing these patterns may aid risk stratification and longitudinal monitoring. Different p‐tau217 operating points may support risk enrichment and prioritization for confirmatory amyloid testing, but require validation before clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsPositron-Emission TomographyAmyloid beta-PeptidesCognitionHumansFemaleMaleBiomarkersCross-Sectional StudiesAgedAlzheimer DiseasePhosphorylationAged, 80 and overDisease ProgressionBrain

Stichwörter der Autor:innen

Centiloidamyloid positron emission tomographycognitively unimpaireddiscordanceplasma phosphorylated tau 217

Substanzen

tau ProteinsBiomarkersAmyloid beta-PeptidesMAPT protein, human

Autor:innen und Institutionen

  • Health Management Center, Shenzhen Qianhai Taikang Hospital, Shenzhen, China.
  • Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Neurosurgery Center, The National Key Clinical Specialty, Engineering Research Center of Diagnostic and Therapeutic Technology and Devices for Cerebrovascular Diseases in Ministry of Education, Guangdong Provincial Key…

ORCID-Profile: Fang Xie

Förderung

  • National Institute on Aging (NIA), National Institutes of Health (NIH)
  • National Science and Technology Major Project of China
  • STI2030-Major Projects
  • Sjtu Trans-med Awards Research
  • National Natural Science Foundation of China

Zitieren

APA

Huang, Y., Huang, L., Cui, L., Pan, F., Xie, F., Guo, H., Guo, Q., & Alzheimer's Disease Neuroimaging Initiative (2026). Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71922

Vancouver

Huang Y, Huang L, Cui L, Pan F, Xie F, Guo H, et al. Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71922

BibTeX
@article{Huang2026,
  author = {Huang, Yanlu and Huang, Lin and Cui, Liang and Pan, Fengfeng and Xie, Fang and Guo, Hongbo and Guo, Qihao and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {10},
  doi = {10.1002/alz.71922}
}
Kostenlos starten →